November 21st 2024
The companies will collaborate to create and test circVec DNA–LNP formulations for use in potential therapeutic applications.
Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.
Fifty Percent of MS Patients Avoid Treatment Over Injectable Delivery Fears
November 19th 2009Around half of all multiple sclerosis (MS) patients that are eligible for treatment do not receive it and one in five of those patients that do begin therapy, delay doing so because of fear and anxiety over the treatment process, and not fear and anxiety about the disease.